DE69505487D1 - Erythromycin-Derivate, Verfahren zur Herstellung und Verwendung als Arzneimittel - Google Patents

Erythromycin-Derivate, Verfahren zur Herstellung und Verwendung als Arzneimittel

Info

Publication number
DE69505487D1
DE69505487D1 DE69505487T DE69505487T DE69505487D1 DE 69505487 D1 DE69505487 D1 DE 69505487D1 DE 69505487 T DE69505487 T DE 69505487T DE 69505487 T DE69505487 T DE 69505487T DE 69505487 D1 DE69505487 D1 DE 69505487D1
Authority
DE
Germany
Prior art keywords
medicines
manufacture
erythromycin derivatives
formula
erythromycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69505487T
Other languages
English (en)
Other versions
DE69505487T2 (de
Inventor
Constantin Agouridas
Jean-Francois Chantot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Hoechst Marion Roussel
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel, Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel
Publication of DE69505487D1 publication Critical patent/DE69505487D1/de
Application granted granted Critical
Publication of DE69505487T2 publication Critical patent/DE69505487T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69505487T 1994-12-09 1995-12-06 Erythromycin-Derivate, Verfahren zur Herstellung und Verwendung als Arzneimittel Expired - Lifetime DE69505487T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9414807A FR2727969B1 (fr) 1994-12-09 1994-12-09 Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments

Publications (2)

Publication Number Publication Date
DE69505487D1 true DE69505487D1 (de) 1998-11-26
DE69505487T2 DE69505487T2 (de) 1999-05-12

Family

ID=9469625

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69505487T Expired - Lifetime DE69505487T2 (de) 1994-12-09 1995-12-06 Erythromycin-Derivate, Verfahren zur Herstellung und Verwendung als Arzneimittel

Country Status (14)

Country Link
US (1) US5786339A (de)
EP (1) EP0716093B1 (de)
JP (1) JP4083824B2 (de)
KR (1) KR100371473B1 (de)
CN (1) CN1067077C (de)
AT (1) ATE172467T1 (de)
AU (1) AU697876B2 (de)
CA (1) CA2164798C (de)
DE (1) DE69505487T2 (de)
DK (1) DK0716093T3 (de)
ES (1) ES2123934T3 (de)
FR (1) FR2727969B1 (de)
HU (1) HU215192B (de)
ZA (1) ZA9510447B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2745290B1 (fr) * 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
USRE38520E1 (en) * 1996-02-28 2004-05-18 Aventis Pharma S.A. Erythromycin derivatives, method for preparing same, and use thereof as drugs
DE19652362A1 (de) 1996-12-17 1998-06-18 Thomson Brandt Gmbh Verfahren und Vorrichtung zur Kompensation der durch die Verarbeitung von Chrominanz-Signalen entstehenden Luminanzdefekte
US5972898A (en) * 1998-03-27 1999-10-26 Abbott Laboratories 3',3-N-bis-substituted macrolide LHRH antagonists
US5955440A (en) * 1998-03-27 1999-09-21 Abbott Laboratories Macrolide LHRH antagonists
US6020521A (en) * 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) * 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
DE69926005T2 (de) 1998-09-22 2006-05-18 Pfizer Products Inc., Groton Carbamat- und carbazatketolidantibiotika
FR2785612A1 (fr) * 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) * 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
EP1137654A1 (de) 1998-12-10 2001-10-04 Pfizer Products Inc. Carbamat- und carbazat-ketolide antibiotika
HUP0105190A3 (en) * 1999-01-27 2003-03-28 Pfizer Prod Inc Ketolide antibiotics, medicaments containing them and their use
CN1351608A (zh) * 1999-05-24 2002-05-29 辉瑞产品公司 13－甲基红霉素衍生物
WO2001010878A1 (fr) * 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
AU6183800A (en) * 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
AU6316400A (en) * 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
ID27331A (id) * 1999-09-29 2001-03-29 Pfizer Prod Inc Pembuatan antibiotik-antibiotik ketolida karbamat
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
EP1146051A3 (de) * 2000-04-10 2001-10-31 Pfizer Products Inc. Erythromycin A-Derivate
US20050014706A1 (en) * 2003-07-14 2005-01-20 Kanakeshwari Falzari Method of treating tuberculosis
WO2006080954A1 (en) * 2004-07-28 2006-08-03 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
PT1836211E (pt) * 2004-12-21 2010-04-08 Pfizer Prod Inc Macrólidos
US10130465B2 (en) 2016-02-23 2018-11-20 Abbott Cardiovascular Systems Inc. Bifurcated tubular graft for treating tricuspid regurgitation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114589A (en) * 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of the history of erythromycin
FR2692579B1 (fr) * 1992-06-19 1995-06-02 Roussel Uclaf Nouveaux dérivés de la picromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) * 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) * 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
HRP930014A2 (en) * 1993-01-08 1994-08-31 Pliva Pharm & Chem Works 9-deoxo-9a-aza-11-deoxy-9a-homoeritromycin a 9a, 11-cyclic carbamates
JPH07219312A (ja) * 1993-12-10 1995-08-18 Canon Inc 画像形成装置

Also Published As

Publication number Publication date
FR2727969B1 (fr) 1997-01-17
CA2164798C (fr) 2007-03-20
JP4083824B2 (ja) 2008-04-30
US5786339A (en) 1998-07-28
ES2123934T3 (es) 1999-01-16
EP0716093A1 (de) 1996-06-12
HUT74075A (en) 1996-10-28
EP0716093B1 (de) 1998-10-21
JPH08231583A (ja) 1996-09-10
HU215192B (hu) 1998-10-28
HU9503524D0 (en) 1996-02-28
FR2727969A1 (fr) 1996-06-14
CN1133291A (zh) 1996-10-16
ATE172467T1 (de) 1998-11-15
KR960022553A (ko) 1996-07-18
KR100371473B1 (ko) 2003-07-22
CA2164798A1 (fr) 1996-06-10
ZA9510447B (en) 1996-12-09
AU697876B2 (en) 1998-10-22
CN1067077C (zh) 2001-06-13
AU4032495A (en) 1996-06-20
DE69505487T2 (de) 1999-05-12
DK0716093T3 (da) 1999-06-28

Similar Documents

Publication Publication Date Title
DE69505487D1 (de) Erythromycin-Derivate, Verfahren zur Herstellung und Verwendung als Arzneimittel
HU9302220D0 (en) Desoxi-taxole derivatives, pharmaceutical preparatives containing them as active agent and methods for producing them
BG101402A (en) Apoliprotein-b synthesis inhibitors
IL66341A0 (en) Pyrrolidine derivatives,their manufacture and pharmaceutical compositions containing them
FI933903A0 (fi) Substituerade cyklohexanderivat, foerfarande foer framstaellning daerav och anvaendning av foereningar foer behandling av sjukdomar
AU559376B2 (en) Disubstituted polymethylene-imines, processes for their preparation
ATE18549T1 (de) 1-carboxyalkanoylindolin-2-carbonsaeure-ester, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen, sowie ihre therapeutische verwendung.
DE3769563D1 (de) Neue derivate von 4,5-dihydro-oxazolen, verfahren zu ihrer herstellung und ihre verwendung.
AU553693B2 (en) Benzodioxine derivatives
PT79751B (de) Neue benzothiazin-derivate verfahren zu ihrer herstellung sie enthaltende arzneimittel und deren verwendung
DE3165993D1 (en) Salts of endo-8-methyl-8-syn-alkyl-8-azoniabicyclo-(3.2.1)-octane-3-alkylcarboxylates, process for their preparation and therapeutic compositions containing them
AU1792395A (en) Cyclohexane derivatives, process for their preparation, and the use of the compounds for the treatment of diseases
ATE13882T1 (de) 1-((substituierte-naphthyl)aethyl)imidazolderivate, sie enthaltende pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung.
AU8329782A (en) Cyclic sulphenamide derivatives
ATE94532T1 (de) Neue leukotrien-b4-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ES8604970A1 (es) Procedimiento para la obtencion de compuestos de 2-heterociclil-alquilo inferior-2-penem
SE8101516L (sv) Nya steroid-spiro-oxatiazolidinderivat jemte sett for deras framstellning
FI933205A (fi) Tiatsolietanolijohdannaisia, menetelmä niiden valmistamiseksi ja niiden välituotteet
ATE49003T1 (de) Pregnane derivate, verfahren zu ihrer herstellung und pharmazeutische zusammenstellungen, die sie enthalten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS PHARMA S.A., ANTONY CEDEX, FR

8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC